Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer One-A-Day

This article was originally published in The Tan Sheet

Executive Summary

Two new products in the specialized supplement line, Bedtime & Rest and Joint Health, will begin shipping July 6 with distribution expected to be completed by August. The 30-count products are the first new introductions to the One-A-Day herbals line. Bedtime & Rest is formulated with kava kava, valerian, magnesium and calcium and Joint Health contains glucosamine, devil's claw, vitamins C and E and manganese. Labeling suggests taking three capsules a day of Joint Health and two capsules of Bedtime & Rest one hour before sleeping. Pricing will be comparable to the rest of the line, which retails for between $8.99 and $9.99. An FSI featuring Bedtime & Rest and Joint Health is scheduled to drop in September along with a TV spot for Joint Health
Advertisement

Related Content

Centrum Line Controls Over One-Third Of Multivitamins Category In 2000
Centrum Line Controls Over One-Third Of Multivitamins Category In 2000
Centrum Line Controls Over One-Third Of Multivitamins Category In 2000
Quanterra Supplement Line Extended With Three New Products
Quanterra Supplement Line Extended With Three New Products
Quanterra Supplement Line Extended With Three New Products
Bayer Keeping One-A-Day Cold Season Name Despite FDA Reservations
Bayer Keeping One-A-Day Cold Season Name Despite FDA Reservations
Bayer Keeping One-A-Day Cold Season Name Despite FDA Reservations

Topics

Advertisement
UsernamePublicRestriction

Register

PS089917

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel